Home Stock

Stock Research: Revance Therapeutics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Revance Therapeutics

NasdaqGM:RVNC US7613301099
n/a
  • Value
    n/a
  • Growth
    n/a
  • Safety
    Safety
    n/a
  • Combined
    n/a
  • Sentiment
    n/a
  • 360° View
    360° View
    n/a
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

more
Analysis
n/a
more
Country USA
Industry Pharmaceuticals
Size Medium
Website revance.com
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: .

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
n/a 82 78 5
Growth
n/a 65 37 21
Safety
Safety
n/a 22 25 41
Sentiment
n/a 12 48 100
360° View
360° View
n/a 44 28 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
n/a 5 47 71
Opinions Change
n/a 50 50 94
Pro Holdings
n/a 1 59 86
Market Pulse
n/a 21 45 64
Sentiment
n/a 12 48 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
n/a 82 78 5
Growth
n/a 65 37 21
Safety Safety
n/a 22 25 41
Combined
n/a 74 42 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
n/a 94 94 6
Price vs. Earnings (P/E)
n/a 76 64 29
Price vs. Book (P/B)
n/a 92 94 10
Dividend Yield
n/a 1 1 1
Value
n/a 82 78 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
n/a 94 87 79
Profit Growth
n/a 48 51 41
Capital Growth
n/a 60 12 5
Stock Returns
n/a 29 17 29
Growth
n/a 65 37 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
n/a 5 7 53
Refinancing
n/a 77 77 49
Liquidity
n/a 21 22 15
Safety Safety
n/a 22 25 41

Similar Stocks

Discover high‑ranked alternatives to Revance Therapeutics and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis
OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.